REDWOOD CITY, Calif., April 11, 2008 (PRIME NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced multiple presentations regarding its oncology pipeline, which includes three preclinical presentations on its hypoxia-activated prodrugs. TH-302, the lead hypoxia-activated prodrug, began a Phase 1 clinical trial in July 2007 and plans to enter Phase 1 and 2 studies with docetaxel, gemcitabine, and pemetrexed in the third quarter of 2008. The presentations will take place at the 2008 American Association for Cancer Research (AACR) annual meeting being held April 12 - 16, 2008, at the San Diego Convention Center in San Diego, CA.
